Edwin Moses
Presidente presso AVANTIUM N.V.
Patrimonio netto: 787 032 $ in data 31/05/2024
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Karl Peggs | M | 57 |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | 8 anni |
Iraj Ali | M | 48 |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | 6 anni |
Jean-Michel Beghin | M | 58 |
Keensight Capital SAS
Keensight Capital SAS Investment ManagersFinance Keensight Capital SAS (Keensight) is an independent French venture capital firm which was established in 2001. Formerly known as R Capital Management SAS, a subsidiary of the Rothschild Group, the firm became independent in 2013 and changed their name to Keensight Capital. Keensight is located in Paris and manages venture capital investments, including the FCPR R Capital Technologies for a range of clients including European banks, pension schemes, insurance companies, government-controlled entities, fund of funds, family offices and high-net worth private individuals. | 11 anni |
Jérôme Pujol | M | - |
Keensight Capital SAS
Keensight Capital SAS Investment ManagersFinance Keensight Capital SAS (Keensight) is an independent French venture capital firm which was established in 2001. Formerly known as R Capital Management SAS, a subsidiary of the Rothschild Group, the firm became independent in 2013 and changed their name to Keensight Capital. Keensight is located in Paris and manages venture capital investments, including the FCPR R Capital Technologies for a range of clients including European banks, pension schemes, insurance companies, government-controlled entities, fund of funds, family offices and high-net worth private individuals. | 11 anni |
Pierre Rémy | M | 57 |
Keensight Capital SAS
Keensight Capital SAS Investment ManagersFinance Keensight Capital SAS (Keensight) is an independent French venture capital firm which was established in 2001. Formerly known as R Capital Management SAS, a subsidiary of the Rothschild Group, the firm became independent in 2013 and changed their name to Keensight Capital. Keensight is located in Paris and manages venture capital investments, including the FCPR R Capital Technologies for a range of clients including European banks, pension schemes, insurance companies, government-controlled entities, fund of funds, family offices and high-net worth private individuals. | 11 anni |
Philippe Crochet | M | - |
Keensight Capital SAS
Keensight Capital SAS Investment ManagersFinance Keensight Capital SAS (Keensight) is an independent French venture capital firm which was established in 2001. Formerly known as R Capital Management SAS, a subsidiary of the Rothschild Group, the firm became independent in 2013 and changed their name to Keensight Capital. Keensight is located in Paris and manages venture capital investments, including the FCPR R Capital Technologies for a range of clients including European banks, pension schemes, insurance companies, government-controlled entities, fund of funds, family offices and high-net worth private individuals. | 11 anni |
Josh Distler | M | 48 |
Oak Hill Bio Corp.
Oak Hill Bio Corp. Miscellaneous Commercial ServicesCommercial Services Oak Hill Bio, Inc. is a clinical-stage rare disease therapeutics company. It develops life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases. The firm has operations in the United States and United Kingdom to develop a pipeline of clinical-stage and pre-clinical investigational therapeutics acquired and licensed from Takeda Pharmaceutical Company Limited. The company is headquartered in Cambridge, MA. | - |
Michael Giordano | M | 66 |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | 6 anni |
Carsten Boess | M | 57 |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | 4 anni |
William Graham Richards | M | 85 |
Oxford Drug Design Ltd.
Oxford Drug Design Ltd. Packaged SoftwareTechnology Services Oxford Drug Design Ltd. develops application of new technologies to drive computer-aided drug discovery. It specializes in drug discovery, molecular modeling, lead identification and optimisation, formulation modeling and preclinical studies. The company was founded by W. Graham Richards in 2001 and is headquartered in Oxford, the United Kingdom. | 23 anni |
Tom B. van Aken | M | 53 | 22 anni | |
James Field | M | 36 |
Labgenius Ltd.
Labgenius Ltd. Pharmaceuticals: MajorHealth Technology Labgenius Ltd. discovers novel and optimized biological molecules using artificial intelligence, automation and synthetic DNA. It specializes in synthetic biology, DNA libraries, protein engineering, artificial intelligence and machine learning. The company was founded by James Field in 2012 and is headquartered in London, the United Kingdom. | 12 anni |
Bernhard R. M. Ehmer | M | 69 | 2 anni | |
Javier Lopez Moras | M | - |
Keensight Capital SAS
Keensight Capital SAS Investment ManagersFinance Keensight Capital SAS (Keensight) is an independent French venture capital firm which was established in 2001. Formerly known as R Capital Management SAS, a subsidiary of the Rothschild Group, the firm became independent in 2013 and changed their name to Keensight Capital. Keensight is located in Paris and manages venture capital investments, including the FCPR R Capital Technologies for a range of clients including European banks, pension schemes, insurance companies, government-controlled entities, fund of funds, family offices and high-net worth private individuals. | 7 anni |
Arnaud Cohen | M | - |
Keensight Capital SAS
Keensight Capital SAS Investment ManagersFinance Keensight Capital SAS (Keensight) is an independent French venture capital firm which was established in 2001. Formerly known as R Capital Management SAS, a subsidiary of the Rothschild Group, the firm became independent in 2013 and changed their name to Keensight Capital. Keensight is located in Paris and manages venture capital investments, including the FCPR R Capital Technologies for a range of clients including European banks, pension schemes, insurance companies, government-controlled entities, fund of funds, family offices and high-net worth private individuals. | 7 anni |
Sergio Quezada | M | 49 | 4 anni | |
Mark McHale | M | 59 |
Oak Hill Bio Corp.
Oak Hill Bio Corp. Miscellaneous Commercial ServicesCommercial Services Oak Hill Bio, Inc. is a clinical-stage rare disease therapeutics company. It develops life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases. The firm has operations in the United States and United Kingdom to develop a pipeline of clinical-stage and pre-clinical investigational therapeutics acquired and licensed from Takeda Pharmaceutical Company Limited. The company is headquartered in Cambridge, MA. | 2 anni |
Margret G. Kleinsman | F | 60 | 7 anni | |
Daniel Hood | M | - | - | |
Ludwig Goris | M | - |
Capricorn Partners NV
Capricorn Partners NV Investment ManagersFinance Capricorn Partners NV (Capricorn) is an independent European licensed manager of private and public equity investment funds which was founded in 1993 as a joint venture between Dr Jos B. Peeters and Baring Venture Partners Ltd. In 1999, Capricorn became a fully partner-owned, independent firm. It is headquartered in Leuven, Belgium. | 13 anni |
Carlo Cartapani | M | - |
Keensight Capital SAS
Keensight Capital SAS Investment ManagersFinance Keensight Capital SAS (Keensight) is an independent French venture capital firm which was established in 2001. Formerly known as R Capital Management SAS, a subsidiary of the Rothschild Group, the firm became independent in 2013 and changed their name to Keensight Capital. Keensight is located in Paris and manages venture capital investments, including the FCPR R Capital Technologies for a range of clients including European banks, pension schemes, insurance companies, government-controlled entities, fund of funds, family offices and high-net worth private individuals. | 5 anni |
Amit Karna | M | - |
Keensight Capital SAS
Keensight Capital SAS Investment ManagersFinance Keensight Capital SAS (Keensight) is an independent French venture capital firm which was established in 2001. Formerly known as R Capital Management SAS, a subsidiary of the Rothschild Group, the firm became independent in 2013 and changed their name to Keensight Capital. Keensight is located in Paris and manages venture capital investments, including the FCPR R Capital Technologies for a range of clients including European banks, pension schemes, insurance companies, government-controlled entities, fund of funds, family offices and high-net worth private individuals. | 5 anni |
Jan Kinsky | M | - |
Keensight Capital SAS
Keensight Capital SAS Investment ManagersFinance Keensight Capital SAS (Keensight) is an independent French venture capital firm which was established in 2001. Formerly known as R Capital Management SAS, a subsidiary of the Rothschild Group, the firm became independent in 2013 and changed their name to Keensight Capital. Keensight is located in Paris and manages venture capital investments, including the FCPR R Capital Technologies for a range of clients including European banks, pension schemes, insurance companies, government-controlled entities, fund of funds, family offices and high-net worth private individuals. | 6 anni |
Dara Henry | M | - |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | - |
Marie Yurkovich | M | - |
Oak Hill Bio Corp.
Oak Hill Bio Corp. Miscellaneous Commercial ServicesCommercial Services Oak Hill Bio, Inc. is a clinical-stage rare disease therapeutics company. It develops life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases. The firm has operations in the United States and United Kingdom to develop a pipeline of clinical-stage and pre-clinical investigational therapeutics acquired and licensed from Takeda Pharmaceutical Company Limited. The company is headquartered in Cambridge, MA. | - |
Léa Najmark | F | - |
Keensight Capital SAS
Keensight Capital SAS Investment ManagersFinance Keensight Capital SAS (Keensight) is an independent French venture capital firm which was established in 2001. Formerly known as R Capital Management SAS, a subsidiary of the Rothschild Group, the firm became independent in 2013 and changed their name to Keensight Capital. Keensight is located in Paris and manages venture capital investments, including the FCPR R Capital Technologies for a range of clients including European banks, pension schemes, insurance companies, government-controlled entities, fund of funds, family offices and high-net worth private individuals. | 4 anni |
Adrien van Eynde | M | - |
Keensight Capital SAS
Keensight Capital SAS Investment ManagersFinance Keensight Capital SAS (Keensight) is an independent French venture capital firm which was established in 2001. Formerly known as R Capital Management SAS, a subsidiary of the Rothschild Group, the firm became independent in 2013 and changed their name to Keensight Capital. Keensight is located in Paris and manages venture capital investments, including the FCPR R Capital Technologies for a range of clients including European banks, pension schemes, insurance companies, government-controlled entities, fund of funds, family offices and high-net worth private individuals. | 6 anni |
Jean Christophe Cini | M | - |
Keensight Capital SAS
Keensight Capital SAS Investment ManagersFinance Keensight Capital SAS (Keensight) is an independent French venture capital firm which was established in 2001. Formerly known as R Capital Management SAS, a subsidiary of the Rothschild Group, the firm became independent in 2013 and changed their name to Keensight Capital. Keensight is located in Paris and manages venture capital investments, including the FCPR R Capital Technologies for a range of clients including European banks, pension schemes, insurance companies, government-controlled entities, fund of funds, family offices and high-net worth private individuals. | 7 anni |
Arjan Hannink | M | - |
Keensight Capital SAS
Keensight Capital SAS Investment ManagersFinance Keensight Capital SAS (Keensight) is an independent French venture capital firm which was established in 2001. Formerly known as R Capital Management SAS, a subsidiary of the Rothschild Group, the firm became independent in 2013 and changed their name to Keensight Capital. Keensight is located in Paris and manages venture capital investments, including the FCPR R Capital Technologies for a range of clients including European banks, pension schemes, insurance companies, government-controlled entities, fund of funds, family offices and high-net worth private individuals. | 5 anni |
Magdalena Svensson | F | - |
Keensight Capital SAS
Keensight Capital SAS Investment ManagersFinance Keensight Capital SAS (Keensight) is an independent French venture capital firm which was established in 2001. Formerly known as R Capital Management SAS, a subsidiary of the Rothschild Group, the firm became independent in 2013 and changed their name to Keensight Capital. Keensight is located in Paris and manages venture capital investments, including the FCPR R Capital Technologies for a range of clients including European banks, pension schemes, insurance companies, government-controlled entities, fund of funds, family offices and high-net worth private individuals. | 10 anni |
Michelle Jou | F | 55 | 4 anni | |
Stephane Jamin | M | - |
Keensight Capital SAS
Keensight Capital SAS Investment ManagersFinance Keensight Capital SAS (Keensight) is an independent French venture capital firm which was established in 2001. Formerly known as R Capital Management SAS, a subsidiary of the Rothschild Group, the firm became independent in 2013 and changed their name to Keensight Capital. Keensight is located in Paris and manages venture capital investments, including the FCPR R Capital Technologies for a range of clients including European banks, pension schemes, insurance companies, government-controlled entities, fund of funds, family offices and high-net worth private individuals. | 4 anni |
Nicolas Ulrich | M | - |
Keensight Capital SAS
Keensight Capital SAS Investment ManagersFinance Keensight Capital SAS (Keensight) is an independent French venture capital firm which was established in 2001. Formerly known as R Capital Management SAS, a subsidiary of the Rothschild Group, the firm became independent in 2013 and changed their name to Keensight Capital. Keensight is located in Paris and manages venture capital investments, including the FCPR R Capital Technologies for a range of clients including European banks, pension schemes, insurance companies, government-controlled entities, fund of funds, family offices and high-net worth private individuals. | 7 anni |
Tauhid Ali | M | 56 |
Oak Hill Bio Corp.
Oak Hill Bio Corp. Miscellaneous Commercial ServicesCommercial Services Oak Hill Bio, Inc. is a clinical-stage rare disease therapeutics company. It develops life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases. The firm has operations in the United States and United Kingdom to develop a pipeline of clinical-stage and pre-clinical investigational therapeutics acquired and licensed from Takeda Pharmaceutical Company Limited. The company is headquartered in Cambridge, MA. | 2 anni |
Shree Patel | M | - | - | |
Tariq Ahmed | M | - | 4 anni | |
Edward Samuel | M | - | 2 anni | |
Liz Elmhirst | F | - |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | - |
James Taylor | M | - | 2 anni | |
Steven Olivier | M | 60 | - | |
Rohan Ganesh | M | - |
Labgenius Ltd.
Labgenius Ltd. Pharmaceuticals: MajorHealth Technology Labgenius Ltd. discovers novel and optimized biological molecules using artificial intelligence, automation and synthetic DNA. It specializes in synthetic biology, DNA libraries, protein engineering, artificial intelligence and machine learning. The company was founded by James Field in 2012 and is headquartered in London, the United Kingdom. | 1 anni |
Shaq Vayda | M | - |
Labgenius Ltd.
Labgenius Ltd. Pharmaceuticals: MajorHealth Technology Labgenius Ltd. discovers novel and optimized biological molecules using artificial intelligence, automation and synthetic DNA. It specializes in synthetic biology, DNA libraries, protein engineering, artificial intelligence and machine learning. The company was founded by James Field in 2012 and is headquartered in London, the United Kingdom. | 2 anni |
Boudewijn van Schaïk | M | - | 1 anni | |
Victoria Niklas | M | 64 |
Oak Hill Bio Corp.
Oak Hill Bio Corp. Miscellaneous Commercial ServicesCommercial Services Oak Hill Bio, Inc. is a clinical-stage rare disease therapeutics company. It develops life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases. The firm has operations in the United States and United Kingdom to develop a pipeline of clinical-stage and pre-clinical investigational therapeutics acquired and licensed from Takeda Pharmaceutical Company Limited. The company is headquartered in Cambridge, MA. | 2 anni |
Robert Coutts | M | 40 | 4 anni | |
Derek DiRocco | M | 43 |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | - |
Remi Louvel | M | - |
Keensight Capital SAS
Keensight Capital SAS Investment ManagersFinance Keensight Capital SAS (Keensight) is an independent French venture capital firm which was established in 2001. Formerly known as R Capital Management SAS, a subsidiary of the Rothschild Group, the firm became independent in 2013 and changed their name to Keensight Capital. Keensight is located in Paris and manages venture capital investments, including the FCPR R Capital Technologies for a range of clients including European banks, pension schemes, insurance companies, government-controlled entities, fund of funds, family offices and high-net worth private individuals. | 7 anni |
Anne de Bonnefon | F | - |
Keensight Capital SAS
Keensight Capital SAS Investment ManagersFinance Keensight Capital SAS (Keensight) is an independent French venture capital firm which was established in 2001. Formerly known as R Capital Management SAS, a subsidiary of the Rothschild Group, the firm became independent in 2013 and changed their name to Keensight Capital. Keensight is located in Paris and manages venture capital investments, including the FCPR R Capital Technologies for a range of clients including European banks, pension schemes, insurance companies, government-controlled entities, fund of funds, family offices and high-net worth private individuals. | 8 anni |
Ramy Farid | M | 59 |
Oak Hill Bio Corp.
Oak Hill Bio Corp. Miscellaneous Commercial ServicesCommercial Services Oak Hill Bio, Inc. is a clinical-stage rare disease therapeutics company. It develops life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases. The firm has operations in the United States and United Kingdom to develop a pipeline of clinical-stage and pre-clinical investigational therapeutics acquired and licensed from Takeda Pharmaceutical Company Limited. The company is headquartered in Cambridge, MA. | 2 anni |
José Luis Martín | M | - |
Keensight Capital SAS
Keensight Capital SAS Investment ManagersFinance Keensight Capital SAS (Keensight) is an independent French venture capital firm which was established in 2001. Formerly known as R Capital Management SAS, a subsidiary of the Rothschild Group, the firm became independent in 2013 and changed their name to Keensight Capital. Keensight is located in Paris and manages venture capital investments, including the FCPR R Capital Technologies for a range of clients including European banks, pension schemes, insurance companies, government-controlled entities, fund of funds, family offices and high-net worth private individuals. | 4 anni |
David Colpman | M | 62 |
Oak Hill Bio Corp.
Oak Hill Bio Corp. Miscellaneous Commercial ServicesCommercial Services Oak Hill Bio, Inc. is a clinical-stage rare disease therapeutics company. It develops life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases. The firm has operations in the United States and United Kingdom to develop a pipeline of clinical-stage and pre-clinical investigational therapeutics acquired and licensed from Takeda Pharmaceutical Company Limited. The company is headquartered in Cambridge, MA. | 2 anni |
Nan Li | M | - |
Labgenius Ltd.
Labgenius Ltd. Pharmaceuticals: MajorHealth Technology Labgenius Ltd. discovers novel and optimized biological molecules using artificial intelligence, automation and synthetic DNA. It specializes in synthetic biology, DNA libraries, protein engineering, artificial intelligence and machine learning. The company was founded by James Field in 2012 and is headquartered in London, the United Kingdom. | 5 anni |
Gregory Agez | M | - |
Keensight Capital SAS
Keensight Capital SAS Investment ManagersFinance Keensight Capital SAS (Keensight) is an independent French venture capital firm which was established in 2001. Formerly known as R Capital Management SAS, a subsidiary of the Rothschild Group, the firm became independent in 2013 and changed their name to Keensight Capital. Keensight is located in Paris and manages venture capital investments, including the FCPR R Capital Technologies for a range of clients including European banks, pension schemes, insurance companies, government-controlled entities, fund of funds, family offices and high-net worth private individuals. | 11 anni |
Guillaume Lefebvre | M | - |
Keensight Capital SAS
Keensight Capital SAS Investment ManagersFinance Keensight Capital SAS (Keensight) is an independent French venture capital firm which was established in 2001. Formerly known as R Capital Management SAS, a subsidiary of the Rothschild Group, the firm became independent in 2013 and changed their name to Keensight Capital. Keensight is located in Paris and manages venture capital investments, including the FCPR R Capital Technologies for a range of clients including European banks, pension schemes, insurance companies, government-controlled entities, fund of funds, family offices and high-net worth private individuals. | 10 anni |
Daniel Curran | M | 57 |
Oak Hill Bio Corp.
Oak Hill Bio Corp. Miscellaneous Commercial ServicesCommercial Services Oak Hill Bio, Inc. is a clinical-stage rare disease therapeutics company. It develops life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases. The firm has operations in the United States and United Kingdom to develop a pipeline of clinical-stage and pre-clinical investigational therapeutics acquired and licensed from Takeda Pharmaceutical Company Limited. The company is headquartered in Cambridge, MA. | 2 anni |
Caroline van Reedt Dortland | F | - | 6 anni | |
Charles Bonnassieux | M | - |
Keensight Capital SAS
Keensight Capital SAS Investment ManagersFinance Keensight Capital SAS (Keensight) is an independent French venture capital firm which was established in 2001. Formerly known as R Capital Management SAS, a subsidiary of the Rothschild Group, the firm became independent in 2013 and changed their name to Keensight Capital. Keensight is located in Paris and manages venture capital investments, including the FCPR R Capital Technologies for a range of clients including European banks, pension schemes, insurance companies, government-controlled entities, fund of funds, family offices and high-net worth private individuals. | 3 anni |
Nils Björkman | M | 70 | 2 anni | |
Zavain Dar | M | 35 |
Labgenius Ltd.
Labgenius Ltd. Pharmaceuticals: MajorHealth Technology Labgenius Ltd. discovers novel and optimized biological molecules using artificial intelligence, automation and synthetic DNA. It specializes in synthetic biology, DNA libraries, protein engineering, artificial intelligence and machine learning. The company was founded by James Field in 2012 and is headquartered in London, the United Kingdom. | - |
Theodor Wuppermann | M | - |
Keensight Capital SAS
Keensight Capital SAS Investment ManagersFinance Keensight Capital SAS (Keensight) is an independent French venture capital firm which was established in 2001. Formerly known as R Capital Management SAS, a subsidiary of the Rothschild Group, the firm became independent in 2013 and changed their name to Keensight Capital. Keensight is located in Paris and manages venture capital investments, including the FCPR R Capital Technologies for a range of clients including European banks, pension schemes, insurance companies, government-controlled entities, fund of funds, family offices and high-net worth private individuals. | 6 anni |
Jaana Grüter | F | - |
Keensight Capital SAS
Keensight Capital SAS Investment ManagersFinance Keensight Capital SAS (Keensight) is an independent French venture capital firm which was established in 2001. Formerly known as R Capital Management SAS, a subsidiary of the Rothschild Group, the firm became independent in 2013 and changed their name to Keensight Capital. Keensight is located in Paris and manages venture capital investments, including the FCPR R Capital Technologies for a range of clients including European banks, pension schemes, insurance companies, government-controlled entities, fund of funds, family offices and high-net worth private individuals. | 9 anni |
Julie O'Neill | F | 58 | 3 anni | |
Rogier Rooswinkel | M | - |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | - |
Carmen Portocarero | F | 57 | 12 anni | |
Ed de Jong | M | - | 17 anni | |
David Piccoli | M | - |
Keensight Capital SAS
Keensight Capital SAS Investment ManagersFinance Keensight Capital SAS (Keensight) is an independent French venture capital firm which was established in 2001. Formerly known as R Capital Management SAS, a subsidiary of the Rothschild Group, the firm became independent in 2013 and changed their name to Keensight Capital. Keensight is located in Paris and manages venture capital investments, including the FCPR R Capital Technologies for a range of clients including European banks, pension schemes, insurance companies, government-controlled entities, fund of funds, family offices and high-net worth private individuals. | 9 anni |
Irina Haivas | F | - |
Labgenius Ltd.
Labgenius Ltd. Pharmaceuticals: MajorHealth Technology Labgenius Ltd. discovers novel and optimized biological molecules using artificial intelligence, automation and synthetic DNA. It specializes in synthetic biology, DNA libraries, protein engineering, artificial intelligence and machine learning. The company was founded by James Field in 2012 and is headquartered in London, the United Kingdom. | - |
Leila Rastegar Zegna | F | 42 |
Labgenius Ltd.
Labgenius Ltd. Pharmaceuticals: MajorHealth Technology Labgenius Ltd. discovers novel and optimized biological molecules using artificial intelligence, automation and synthetic DNA. It specializes in synthetic biology, DNA libraries, protein engineering, artificial intelligence and machine learning. The company was founded by James Field in 2012 and is headquartered in London, the United Kingdom. | - |
Gregory F. Peter | M | - |
Keensight Capital SAS
Keensight Capital SAS Investment ManagersFinance Keensight Capital SAS (Keensight) is an independent French venture capital firm which was established in 2001. Formerly known as R Capital Management SAS, a subsidiary of the Rothschild Group, the firm became independent in 2013 and changed their name to Keensight Capital. Keensight is located in Paris and manages venture capital investments, including the FCPR R Capital Technologies for a range of clients including European banks, pension schemes, insurance companies, government-controlled entities, fund of funds, family offices and high-net worth private individuals. | 1 anni |
Martin Murphy | M | 55 |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | - |
Elisa Petris | M | 45 |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | 8 anni |
Paul Carter | M | 63 |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | 4 anni |
Gert-Jan M. Gruter | M | 61 | 24 anni | |
Rafe Hafeez | M | - |
Keensight Capital SAS
Keensight Capital SAS Investment ManagersFinance Keensight Capital SAS (Keensight) is an independent French venture capital firm which was established in 2001. Formerly known as R Capital Management SAS, a subsidiary of the Rothschild Group, the firm became independent in 2013 and changed their name to Keensight Capital. Keensight is located in Paris and manages venture capital investments, including the FCPR R Capital Technologies for a range of clients including European banks, pension schemes, insurance companies, government-controlled entities, fund of funds, family offices and high-net worth private individuals. | 1 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Russell Greig | M | 71 | - | |
Bo Jesper Hansen | M | 66 | 5 anni | |
Peter John Fellner | M | 80 | 5 anni | |
Frank Bulens | M | 61 |
Capricorn Partners NV
Capricorn Partners NV Investment ManagersFinance Capricorn Partners NV (Capricorn) is an independent European licensed manager of private and public equity investment funds which was founded in 1993 as a joint venture between Dr Jos B. Peeters and Baring Venture Partners Ltd. In 1999, Capricorn became a fully partner-owned, independent firm. It is headquartered in Leuven, Belgium. | 17 anni |
Scott Myers | M | 57 | 2 anni | |
Catherine Moukheibir | F | 64 | 5 anni | |
Cornelis Verhaar | M | 70 | 2 anni | |
Eva-Lotta Allan | F | 65 | 7 anni | |
Jim Sutcliffe | M | - |
Paradigm Therapeutics Ltd.
Paradigm Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Paradigm Therapeutics Ltd. discovers and develops drugs. The genomics-based drug discovery company uses research methods including model mouse genetics, bioinformatics and molecular biology to identify genes that serve as drug targets. The company has launched a subsidiary research center in Singapore. The company was founded in 1999 by Aparicio Samuel and Mark Carlton and is headquartered in Cambridge, UK. | - |
Mark Carlton | M | - |
Paradigm Therapeutics Ltd.
Paradigm Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Paradigm Therapeutics Ltd. discovers and develops drugs. The genomics-based drug discovery company uses research methods including model mouse genetics, bioinformatics and molecular biology to identify genes that serve as drug targets. The company has launched a subsidiary research center in Singapore. The company was founded in 1999 by Aparicio Samuel and Mark Carlton and is headquartered in Cambridge, UK. | 8 anni |
Remi Vermeiren | M | 84 | - | |
Mats Gunnar Pettersson | M | 78 | 6 anni | |
William John Jenkins | M | 77 | - | |
Hilde Windels | F | 59 | 1 anni | |
Denis Lucquin | M | 67 | 18 anni | |
Alastair Riddell | M | 74 |
Paradigm Therapeutics Ltd.
Paradigm Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Paradigm Therapeutics Ltd. discovers and develops drugs. The genomics-based drug discovery company uses research methods including model mouse genetics, bioinformatics and molecular biology to identify genes that serve as drug targets. The company has launched a subsidiary research center in Singapore. The company was founded in 1999 by Aparicio Samuel and Mark Carlton and is headquartered in Cambridge, UK. | 2 anni |
Wim Ottevaere | M | 68 | 12 anni | |
Lutgart A. A. van den Berghe | M | 72 | - | |
Patrick J. Langlois | M | 78 | 5 anni | |
Geert Cauwenbergh | M | 70 | 6 anni | |
Roger Perlmutter | M | 71 | 1 anni | |
Piet Houwen | M | 57 | - | |
Barry Kenny | M | - |
Paradigm Therapeutics Ltd.
Paradigm Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Paradigm Therapeutics Ltd. discovers and develops drugs. The genomics-based drug discovery company uses research methods including model mouse genetics, bioinformatics and molecular biology to identify genes that serve as drug targets. The company has launched a subsidiary research center in Singapore. The company was founded in 1999 by Aparicio Samuel and Mark Carlton and is headquartered in Cambridge, UK. | 4 anni |
Vimal Mehta | M | 63 |
Galapagos Biotech Ltd.
Galapagos Biotech Ltd. BiotechnologyHealth Technology Galapagos Biotech Ltd. operates as a drug discovery company which provides discovery technologies and services. Its technologies include Chemogenomics and Silico. The company was founded by Kenneth Leslie Powell and Janet Maureen Thornton in July 8, 1997 and is headquartered in Cambridge, the United Kingdom. | 4 anni |
Ian Michael Laing | M | 78 |
Oxford Asymmetry International Plc
| 8 anni |
Antonin Rollet de Fougerolles | M | 59 | 5 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Regno Unito | 42 | 42.00% |
Francia | 29 | 29.00% |
Belgio | 18 | 18.00% |
Paesi Bassi | 12 | 12.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Edwin Moses
- Contatti personali